Drugs / Passiflora incarnata
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 41 trial | ||||||
| Phase 4 | NCT03780595 | Sep 2018 → Jun 2019 | substance withdrawal syndrome | Nutricion Medica S.L. | Unknown | No outcome recorded |
| Comparator or background therapy3 trials | ||||||
| Phase 2/3 | NCT02065843 Comparator | Mar → Apr 2014 | impacted teeth, multiple | Federal University of Sergipe | Completed | No outcome recorded |
| Phase 3 | NCT01695616 Comparator | Aug 2013 → Aug 2014 | — | Ache Laboratorios Farmaceuticos S.A. | Withdrawn | No outcome recorded |
| Phase 3 | NCT01665170 Comparator | May → Aug 2012 | — | Pascoe Pharmazeutische Praeparate GmbH | Completed | No outcome recorded |
Evidence & citations 2 cited values
Every value below carries the sentence it was read from. 4 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Passiflora incarnata | “The purpose of this study is to evaluate the effects of Passiflora incarnata and Isoflavone combination in relieving the symptoms associated with Climacteric Syndrome.” NCT01695616 ↗ |
| Route | Oral | “Patients enrolled in this arm will take a tablet twice a day” NCT01695616 ↗ |